FCH
LAB icon

Freestone Capital Holdings’s Standard BioTools LAB Stock Holding History

Freestone Capital Holdings’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,388
Closed -$22K – 462
2024
Q3 		$22K Hold
11,388
– – ﹤0.01% 436
2024
Q2 		$20.2K Hold
11,388
– – ﹤0.01% 459
2024
Q1 		$30.9K Buy
+11,388
New +$27.5K ﹤0.01% 443

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Freestone Capital Holdings's LAB Position: Q4 2024 in Review

Freestone Capital Holdings sold out of Standard BioTools (LAB) in Q4 2024, closing a stake of 11,388 shares — an estimated $22K sold.

Freestone Capital Holdings first reported a position in LAB in Q1 2024 and held it in 3 quarters. The position peaked at $30.9K in Q1 2024. 142 funds tracked by Wall St. Rank hold LAB as of Q4 2024.

  • Freestone Capital Holdings reported no remaining Standard BioTools position as of Q4 2024 after selling out during the quarter.
  • Freestone Capital Holdings sold 11,388 Standard BioTools shares in Q4 2024, an estimated $22K.
  • Freestone Capital Holdings first reported a position in Standard BioTools in Q1 2024 and held it in 3 quarters.
  • Freestone Capital Holdings's Standard BioTools position peaked at $30.9K in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2024.

Based on Freestone Capital Holdings's 13F filing for Q4 2024, filed 6 Feb 2025.